Cutia Therapeutics

A new drug aimed at the treatment of androgenetic alopecia is entering a phase 1 clinical trial imminently as of August 2022. CU-40101 Phase 1 Clinical Trial Cutia Therapeutics is the latest biotechnology company to emerge from behind the scenes and enter the global race for new androgenetic alopecia therapies. Its candidate molecule CU-40101 is…